Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis

References

• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14:e218-28; PMID:23639322; http://dx.doi.org/10.1016/S1470-2045(12)70582-X
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tanchot C, Granier C, Tartour E. Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology 2013; 2:e25444; PMID:24073383; http://dx.doi.org/10.4161/onci.25444
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25:315-22; PMID:16967326; http://dx.doi.org/10.1007/s10555-006-9001-7
   PubMed Web of Science ®Google Scholar
• Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24:25-9; PMID:12495721; http://dx.doi.org/10.1016/S1471-4906(02)00013-3
   PubMed Web of Science ®Google Scholar
• Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-14; PMID:11420041; http://dx.doi.org/10.1016/S1074-7613(01)00151-0
   PubMed Web of Science ®Google Scholar
• Marin V, Montero-Julian FA, Gres S, Boulay V, Bongrand P, Farnarier C, Kaplanski G. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 2001; 167:3435-42; PMID:11544336; http://dx.doi.org/10.4049/jimmunol.167.6.3435
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-54; PMID:7632928
   PubMed Web of Science ®Google Scholar
• Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:73-6; PMID:3491322; http://dx.doi.org/10.1038/324073a0
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8; PMID:16648838; http://dx.doi.org/10.1038/nature04753
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-β induces development of the T(H)17 lineage. Nature 2006; 441:231-4; PMID:16648837; http://dx.doi.org/10.1038/nature04754
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-89; PMID:16473830; http://dx.doi.org/10.1016/j.immuni.2006.01.001
   PubMed Web of Science ®Google Scholar
• Kimura A, Kishimoto T. Th17 cells in inflammation. Int Immunopharmacol 2011; 11:319-22; PMID:21035432; http://dx.doi.org/10.1016/j.intimp.2010.10.004
   PubMed Web of Science ®Google Scholar
• Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22:83-9; PMID:21377916; http://dx.doi.org/10.1016/j.cytogfr.2011.02.003
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86; PMID:14676299; http://dx.doi.org/10.1084/jem.20030152
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and downregulation of Smad7. J Immunol 2004; 172:5149-53; PMID:15100250; http://dx.doi.org/10.4049/jimmunol.172.9.5149
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Nakano M, Terabe F, Kawahata H, Ohkawara T, Han Y, Ripley B, Serada S, Nishikawa T, Kimura A et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 2011; 186:32-40; PMID:21106853; http://dx.doi.org/10.4049/jimmunol.0903314
   PubMed Web of Science ®Google Scholar
• Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF, Becker C. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 2007; 179:2041-5; PMID:17675459; http://dx.doi.org/10.4049/jimmunol.179.4.2041
   PubMed Web of Science ®Google Scholar
• Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009; 102:215-22; PMID:19652871; http://dx.doi.org/10.1160/TH09-05-0297
   PubMed Web of Science ®Google Scholar
• Fan Y, Ye J, Shen F, Zhu Y, Yeghiazarians Y, Zhu W, Chen Y, Lawton MT, Young WL, Yang GY. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008; 28:90-8; PMID:17519976; http://dx.doi.org/10.1038/sj.jcbfm.9600509
   PubMed Web of Science ®Google Scholar
• Ghazizadeh M. Essential role of IL-6 signaling pathway in keloid pathogenesis. J Nippon Med Sch 2007; 74:11-22; PMID:17384473; http://dx.doi.org/10.1272/jnms.74.11
   PubMedGoogle Scholar
• Suzuki S, Mita S, Kamohara H, Sakamoto K, Ishiko T, Ogawa M. IL-6 and IFN-gamma regulation of IL-10 production by human colon carcinoma cells. Int J Oncol 2001; 18:581-6; PMID:11179490
   PubMed Web of Science ®Google Scholar
• Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 2004; 172:4630-6; PMID:15034082; http://dx.doi.org/10.4049/jimmunol.172.7.4630
   PubMed Web of Science ®Google Scholar
• Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226:205-18; PMID:19161426; http://dx.doi.org/10.1111/j.1600-065X.2008.00706.x
   PubMed Web of Science ®Google Scholar
• Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clin Cancer Res 2013; 19:6957-66; PMID:24097873; http://dx.doi.org/10.1158/1078-0432.CCR-13-0926
   PubMed Web of Science ®Google Scholar
• Tredan O, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, Perol D, Saba C, Quiblier F, Blay JY et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer 2011; 11:95; PMID:21406082; http://dx.doi.org/10.1186/1471-2407-11-95
   PubMed Web of Science ®Google Scholar
• Ramsey S, Aitchison M, Graham J, McMillan DC. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer. BJU Int 2008; 102:125-9; PMID:18336617; http://dx.doi.org/10.1111/j.1464-410X.2008.07466.x
   PubMed Web of Science ®Google Scholar
• Duletic-Nacinovic A, Stifter S, Marijic B, Lucin K, Valkovic T, Petranovic D, Jonjic N. Serum IL-6, IL-8, IL-10 and beta2-microglobulin in association with International Prognostic Index in diffuse large B cell lymphoma. Tumori 2008; 94:511-7; PMID:18822687
   PubMed Web of Science ®Google Scholar
• Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 1998; 30:563-71; PMID:9711918
   PubMed Web of Science ®Google Scholar
• Suh SY, Choi YS, Yeom CH, Kwak SM, Yoon HM, Kim DG, Koh SJ, Park J, Lee MA, Lee YJ et al. Interleukin-6 but not tumour necrosis factor-α predicts survival in patients with advanced cancer. Support Care Cancer 2013; 21:3071-7; PMID:23828393; http://dx.doi.org/10.1007/s00520-013-1878-4
   PubMed Web of Science ®Google Scholar
• Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 2012; 3:245-51; PMID:22648739; http://dx.doi.org/10.1007/s13539-012-0075-5
   PubMed Web of Science ®Google Scholar
• Grim-Stieger M, Keilani M, Mader RM, Marosi C, Schmidinger M, Zielinski CC, Fialka-Moser V, Crevenna R. Serum levels of tumour necrosis factor-α and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate–preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy. Eur J Cancer Care (Engl) 2008; 17:454-62; PMID:18637115; http://dx.doi.org/10.1111/j.1365-2354.2007.00874.x
   PubMed Web of Science ®Google Scholar
• Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007; 16:1155-9; PMID:17548678; http://dx.doi.org/10.1158/1055-9965.EPI-07-0093
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Niers TM, Reitsma PH, Buller HR. Plasma cytokine and P-selectin levels in advanced malignancy: prognostic value and impact of low-molecular weight heparin administration. Cancer 2005; 104:2275-81; PMID:16216004; http://dx.doi.org/10.1002/cncr.21485
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Gramignano G, Piras MB. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med (Berl) 2001; 79:406-14; PMID:11466563; http://dx.doi.org/10.1007/s001090100234
   PubMed Web of Science ®Google Scholar
• Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, Martinez-Sales V. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011; 102:35-41; PMID:20607353; http://dx.doi.org/10.1007/s11060-010-0290-x
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113:1605-13; PMID:18683214; http://dx.doi.org/10.1002/cncr.23785
   PubMed Web of Science ®Google Scholar
• Thomas X, Hirschauer C, Troncy J, Assouline D, Joly MO, Fiere D, Archimbaud E. Serum interleukin-6 levels in adult acute myelogenous leukemia: relationship with disease characteristics and outcome. Leuk Lymphoma 1997; 24:291-300; PMID:9156658
   PubMed Web of Science ®Google Scholar
• Kita H, Shiraishi Y, Watanabe K, Suda K, Ohtsuka K, Koshiishi Y, Goya T. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg 2011; 17:454-60; PMID:21881374; http://dx.doi.org/10.5761/atcs.oa.10.01627
   PubMed Web of Science ®Google Scholar
• De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5:649-52; PMID:9538169
   PubMed Web of Science ®Google Scholar
• Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, van der Zee AG, Daemen T, Nijman HW, Kast WM. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007; 13:2385-91; PMID:17438097; http://dx.doi.org/10.1158/1078-0432.CCR-06-1828
   PubMed Web of Science ®Google Scholar
• Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997; 66:27-30; PMID:9234916; http://dx.doi.org/10.1006/gyno.1997.4726
   PubMed Web of Science ®Google Scholar
• Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994; 57:318-23; PMID:8168990; http://dx.doi.org/10.1002/ijc.2910570305
   PubMed Web of Science ®Google Scholar
• Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005; 84:510-6; PMID:15834569; http://dx.doi.org/10.1007/s00277-005-1020-x
   PubMed Web of Science ®Google Scholar
• Novotny A, Emmanuel K, Bartels H, Siewert JR, Holzmann B. [Indicators for early prediction of outcome in sepsis]. Chirurg 2005; 76:837-44; PMID:16094522; http://dx.doi.org/10.1007/s00104-005-1077-z
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gaspar M, Santolaria F, Jarque-Lopez A, Gonzalez-Reimers E, Milena A, de la Vega MJ, Rodriguez-Rodriguez E, Gomez-Sirvent JL. Prognostic value of cytokines in SIRS general medical patients. Cytokine 2001; 15:232-6; PMID:11563884; http://dx.doi.org/10.1006/cyto.2001.0932
   PubMed Web of Science ®Google Scholar
• Viallon A, Guyomarc'h S, Marjollet O, Berger C, Carricajo A, Robert F, Laporte S, Lambert C, Page Y, Zeni F et al. Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin. Eur J Emerg Med 2008; 15:26-33; PMID:18180663; http://dx.doi.org/10.1097/MEJ.0b013e3280ec539b
   PubMed Web of Science ®Google Scholar
• Wu HP, Chen CK, Chung K, Tseng JC, Hua CC, Liu YC, Chuang DY, Yang CH. Serial cytokine levels in patients with severe sepsis. Inflamm Res 2009; 58(7):385-93; PMID:19262987; http://dx.doi.org/10.1007/s00011-009-0003-0
   PubMed Web of Science ®Google Scholar
• Ghani RA, Zainudin S, Ctkong N, Rahman AF, Wafa SR, Mohamad M, Manaf MR, Ismail R. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology (Carlton) 2006; 11:386-93; PMID:17014550; http://dx.doi.org/10.1111/j.1440-1797.2006.00600.x
   PubMed Web of Science ®Google Scholar
• Groeneveld AB, Tacx AN, Bossink AW, van Mierlo GJ, Hack CE. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 2003; 106:106-15; PMID:12672401; http://dx.doi.org/10.1016/S1521-6616(02)00025-6
   PubMed Web of Science ®Google Scholar
• Patel RT, Deen KI, Youngs D, Warwick J, Keighley MR. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81:1306-8; PMID:7953393; http://dx.doi.org/10.1002/bjs.1800810914
   PubMed Web of Science ®Google Scholar
• Bencosme A, Warner A, Healy D, Verme C. Prognostic potential of cytokines, nitrates, and APACHE II score in sepsis. Ann Clin Lab Sci 1996; 26:426-32; PMID:8879360
   PubMed Web of Science ®Google Scholar
• Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 2005; 23:488-93; PMID:15897799; http://dx.doi.org/10.1097/01.shk.0000163802.46355.59
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48; PMID:15308095; http://dx.doi.org/10.1016/j.immuni.2004.07.017
   PubMed Web of Science ®Google Scholar
• Vizio B, Novarino A, Giacobino A, Cristiano C, Prati A, Ciuffreda L, Montrucchio G, Bellone G. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med 2012; 4:70-8; PMID:23060925; http://dx.doi.org/10.3892%2Fetm.2012.553
   PubMed Web of Science ®Google Scholar
• Su C, Zhou C, Zhou S, Xu J. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol 2011; 28:1453-7; PMID:20714944; http://dx.doi.org/10.1007/s12032-010-9645-6
   PubMed Web of Science ®Google Scholar
• Candido EB, Silva LM, Carvalho AT, Lamaita RM, Filho RM, Cota BD, da Silva-Filho AL. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reprod Sci 2013; 20:828-37; PMID:23239818; http://dx.doi.org/10.1177/1933719112466299
   PubMed Web of Science ®Google Scholar
• Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010; 10:203; PMID:20465852; http://dx.doi.org/10.1186/1471-2407-10-203
   PubMed Web of Science ®Google Scholar
• Svobodova S, Topolcan O, Holubec L, Jr., Levy M, Pecen L, Svacina S. Parameters of biological activity in colorectal cancer. Anticancer Res 2011; 31:373-8; PMID:21273626
   PubMed Web of Science ®Google Scholar
• Labidi SI, Menetrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T, Biron P, Blay JY, Ghesquieres H. Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival. Ann Hematol 2010; 89:25-33; PMID:19582455; http://dx.doi.org/10.1007/s00277-009-0777-8
   PubMed Web of Science ®Google Scholar
• Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Kedra B, Lukaszewicz M, Baniukiewicz A, Szmitkowski M. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008; 46:1423-8; PMID:18844497; http://dx.doi.org/10.1515/CCLM.2008.278
   PubMed Web of Science ®Google Scholar
• Lukaszewicz-Zajac M, Mroczko B, Gryko M, Kedra B, Szmitkowski M. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 2011; 11:89-96; PMID:20938721; http://dx.doi.org/10.1007/s10238-010-0114-5
   PubMed Web of Science ®Google Scholar
• Ozdemir F, Aydin F, Yilmaz M, Kavgaci H, Bektas O, Yavuz MN, Yavuz AA. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL). J Exp Clin Cancer Res 2004; 23:485-8; PMID:15595640
   PubMed Web of Science ®Google Scholar
• Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang JC, Linehan WM, Rosenberg SA. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 1998; 159:718-22; PMID:9474133; http://dx.doi.org/10.1016/S0022-5347(01)63709-1
   PubMed Web of Science ®Google Scholar
• Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res 2000; 10:237-41; PMID:10890377; http://dx.doi.org/10.1097/00008390-200010030-00005
   PubMed Web of Science ®Google Scholar
• Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer J Int Du Cancer 2003; 107:22-9; PMID:12925952; http://dx.doi.org/10.1002/ijc.11287
   PubMed Web of Science ®Google Scholar
• Marin V, Montero-Julian F, Gres S, Bongrand P, Farnarier C, Kaplanski G. Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-α-converting enzyme (TACE) type. Eur J Immunol 2002; 32:2965-70; PMID:12355450; http://dx.doi.org/10.1002/1521-4141(2002010)32:10%3c2965::AID-IMMU2965%3e3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006; 63:321-9; PMID:16640655; http://dx.doi.org/10.1111/j.1365-3083.2006.01750.x
   PubMed Web of Science ®Google Scholar
• Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005; 28:187-96; PMID:16129903; http://dx.doi.org/10.1385/CRIAI:28:3:187
   PubMed Web of Science ®Google Scholar
• Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110:1911-28; PMID:17849470; http://dx.doi.org/10.1002/cncr.22999
   PubMed Web of Science ®Google Scholar
• O'Reilly S, Ciechomska M, Cant R, Hugle T, van Laar JM. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012; 23:99-107; PMID:22561547; http://dx.doi.org/10.1016/j.cytogfr.2012.04.003
   PubMed Web of Science ®Google Scholar
• Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon β 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987; 84:7251-5; PMID:2444978; http://dx.doi.org/10.1073/pnas.84.20.7251
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Ann Rev Immunol 2009; 27:485-517; PMID:19132915; http://dx.doi.org/10.1146/annurev.immunol.021908.132710
   PubMed Web of Science ®Google Scholar
• Afford SC, Pongracz J, Stockley RA, Crocker J, Burnett D. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U937 and human neutrophils. J Biol Chem 1992; 267:21612-6; PMID:1400472
   PubMed Web of Science ®Google Scholar
• Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011; 41:2522-5; PMID:21952810; http://dx.doi.org/10.1002/eji.201141894
   PubMed Web of Science ®Google Scholar
• Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009; 284:34342-54; PMID:19833726; http://dx.doi.org/10.1074/jbc.M109.042671
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010; 95:31-53; PMID:21075328; http://dx.doi.org/10.1016/B978-0-12-385071-3.00003-4
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4:540-50; PMID:15229479; http://dx.doi.org/10.1038/nrc1388
   PubMed Web of Science ®Google Scholar
• Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997; 150:1723-34; PMID:9137096
   PubMed Web of Science ®Google Scholar
• Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8:253-78; PMID:2188664; http://dx.doi.org/10.1146/annurev.iy.08.040190.001345
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85:2526-31; PMID:10375098; http://dx.doi.org/10.1002/(SICI)1097-0142(19990615)85:12%3c2526::AID-CNCR6%3e3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013; 12:26; PMID:23561329; http://dx.doi.org/10.1186/1476-4598-12-26
   PubMed Web of Science ®Google Scholar
• Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'Eng FK, Chi CW. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996; 91:1417-22; PMID:8678006
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Ichiki Y, Yamada S, Shigematsu Y, Baba T, Nagata Y, Mizukami M, Sugaya M, Takenoyama M, Hanagiri T et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci 2007; 98:1048-54.; PMID:17511773; http://dx.doi.org/10.1111/j.1349-7006.2007.00507.x
   PubMed Web of Science ®Google Scholar
• Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006; 55:684-98; PMID:16094523; http://dx.doi.org/10.1007/s00262-005-0047-0
   PubMed Web of Science ®Google Scholar
• Chow KC, Chiou SH, Ho SP, Tsai MH, Chen CL, Wang LS, Chi KH. The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncol Rep 2003; 10:813-9; PMID:12792728
   PubMed Web of Science ®Google Scholar
• Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res 2006; 26:3905-11; PMID:17094421
   PubMed Web of Science ®Google Scholar
• Yoon JY, Lafarge S, Dawe D, Lakhi S, Kumar R, Morales C, Marshall A, Gibson SB, Johnston JB. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53:1735-42; PMID:22475215; http://dx.doi.org/10.3109/10428194.2012.666662
   PubMed Web of Science ®Google Scholar
• Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008; 102:756-61; PMID:18384626; http://dx.doi.org/10.1111/j.1464-410X.2008.07666.x
   PubMed Web of Science ®Google Scholar
• Moses AG, Maingay J, Sangster K, Fearon KC, Ross JA. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 2009; 21:1091-5; PMID:19288013; http://dx.doi.org/10.3892/or_00000328
   PubMed Web of Science ®Google Scholar
• Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, Kloters O, Hammer J, Buchler MW, Giese NA et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 2005; 11:5802-8; PMID:16115919; http://dx.doi.org/10.1158/1078-0432.CCR-05-0185
   PubMed Web of Science ®Google Scholar
• Gallo O, Gori AM, Attanasio M, Martini F, Giusti B, Boddi M, Gallina E, Fini O, Abbate R. Interleukin-1 β and interleukin-6 release by peripheral blood monocytes in head and neck cancer. Br J Cancer 1993; 68:465-8; PMID:8353036; http://dx.doi.org/10.1038/bjc.1993.371
   PubMed Web of Science ®Google Scholar
• Monfrecola G, Gaudiello F, Cirillo T, Fabbrocini G, Balato A, Lembo S. Nicotinamide downregulates gene expression of interleukin-6, interleukin-10, monocyte chemoattractant protein-1, and tumour necrosis factor-α gene expression in HaCaT keratinocytes after ultraviolet B irradiation. Clin Exp Dermatol 2013; 38:185-8; PMID:23397947; http://dx.doi.org/10.1111/ced.12018
   PubMed Web of Science ®Google Scholar
• Yue C, You X, Zhao L, Wang H, Tang F, Zhang F, Zhang X, He W. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010; 30:1553-7; PMID:19847432; http://dx.doi.org/10.1007/s00296-009-1179-x
   PubMed Web of Science ®Google Scholar
• Dhillon S. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. BioDrugs 2014; 28:75-106; PMID:24255004; http://dx.doi.org/10.1007/s40259-013-0076-8
   PubMed Web of Science ®Google Scholar
• Assier E, Boissier MC, Dayer JM. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010; 77:532-6; PMID:20869898; http://dx.doi.org/10.1016/j.jbspin.2010.07.007
   PubMed Web of Science ®Google Scholar
• Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE et al. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One 2013; 8:e67059; PMID:23840582; http://dx.doi.org/10.1371/journal.pone.0067059
   PubMedGoogle Scholar
• Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 2013; 108:2063-9; PMID:23591198; http://dx.doi.org/10.1038/bjc.2013.174
   PubMed Web of Science ®Google Scholar
• Arshad A, Chung WY, Steward W, Metcalfe MS, Dennison AR. Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) 2013; 15:428-32; PMID:23458624; http://dx.doi.org/10.1111/hpb.12002
   PubMed Web of Science ®Google Scholar
• Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010; 24:256-61; PMID:20626020; http://dx.doi.org/10.1002/jcla.20395
   PubMed Web of Science ®Google Scholar
• Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011; 9:18; PMID:21294915; http://dx.doi.org/10.1186/1477-7819-9-18
   PubMed Web of Science ®Google Scholar
• Fuksiewicz M, Kowalska M, Kotowicz B, Rubach M, Chechlinska M, Pienkowski T, Kaminska J. Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer. Clin Chem Lab Med 2010; 48:1481-6; PMID:20578967; http://dx.doi.org/10.1515/CCLM.2010.278
   PubMed Web of Science ®Google Scholar
• Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M, Altunbas H, Akan I, Savas B. Tumour necrosis factor-α, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004; 27:58-65; PMID:15242694; http://dx.doi.org/10.1016/j.cyto.2004.04.002
   PubMed Web of Science ®Google Scholar
• Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88:1721-6; PMID:12771987; http://dx.doi.org/10.1038/sj.bjc.6600956
   PubMed Web of Science ®Google Scholar
• Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer J Int Du Cancer 2003; 103:642-6; PMID:12494472; http://dx.doi.org/10.1002/ijc.10833
   PubMed Web of Science ®Google Scholar
• Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19:1427-32; PMID:10365118
   PubMed Web of Science ®Google Scholar
• Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V et al. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 2013; 137:631-6; PMID:23242617; http://dx.doi.org/10.1007/s10549-012-2374-0
   PubMed Web of Science ®Google Scholar
• Shimazaki J, Goto Y, Nishida K, Tabuchi T, Motohashi G, Ubukata H. In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression. Oncology 2013; 84:356-61; PMID:23689116; http://dx.doi.org/10.1159/000350836
   PubMed Web of Science ®Google Scholar
• Yeh KY, Li YY, Hsieh LL, Lu CH, Chou WC, Liaw CC, Tang RP, Liao SK. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol 2010; 40:580-7; PMID:20194250; http://dx.doi.org/10.1093/jjco/hyq010
   PubMed Web of Science ®Google Scholar
• Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005; 11:1639-43; PMID:15786541; http://dx.doi.org/10.3748/wjg.v11.i11.1639
   PubMed Web of Science ®Google Scholar
• Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83:222-6; PMID:12884234; http://dx.doi.org/10.1002/jso.10269
   PubMed Web of Science ®Google Scholar
• Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000; 7:133-8; PMID:10761792; http://dx.doi.org/10.1007/s10434-000-0133-7
   PubMed Web of Science ®Google Scholar
• Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2013; 2:234-42; PMID:23634291; http://dx.doi.org/10.1002/cam4.71
   PubMed Web of Science ®Google Scholar
• Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 2008; 7:331-7; PMID:18794066; http://dx.doi.org/10.3816/CCC.2008.n.044
   PubMed Web of Science ®Google Scholar
• Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus 2012; 25:242-9; PMID:21895853; http://dx.doi.org/10.1111/j.1442-2050.2011.01242.x
   PubMed Web of Science ®Google Scholar
• Hao W, Zhu Y, Zhou H. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013; 30:333; PMID:23269580; http://dx.doi.org/10.1007/s12032-012-0333-6
   PubMed Web of Science ®Google Scholar
• Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995; 71:354-6; PMID:7841052; http://dx.doi.org/10.1038/bjc.1995.71
   PubMed Web of Science ®Google Scholar
• Wang YS, Miao LY, Liu L, Cai HR, Ding JJ, Ren SX, Zhou CC, Schmid-Bindert G. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment. Chin Med J (Engl) 2013; 126:3931-5; PMID:24157160; http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20130578
   PubMed Web of Science ®Google Scholar
• Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977-85; PMID:23034889; http://dx.doi.org/10.1002/ijc.27892
   PubMed Web of Science ®Google Scholar
• Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D, Yoshino N, Takiguchi Y, Tanzawa H. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 2012; 32:3251-8; PMID:22843899
   PubMed Web of Science ®Google Scholar
• Sanchez-Lara K, Turcott JG, Juarez E, Guevara P, Nunez-Valencia C, Onate-Ocana LF, Flores D, Arrieta O. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer 2012; 64:526-34; PMID:22489794; http://dx.doi.org/10.1080/01635581.2012.668744
   PubMed Web of Science ®Google Scholar
• Koh E, Iizasa T, Yamaji H, Sekine Y, Hiroshima K, Yoshino I, Fujisawa T. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol 2012; 20:233-9; PMID:22334615; http://dx.doi.org/10.1177/1066896911436274
   PubMed Web of Science ®Google Scholar
• Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011; 81:360-8; PMID:20888135; http://dx.doi.org/10.1016/j.ijrobp.2010.06.011
   PubMed Web of Science ®Google Scholar
• Songur N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90:196-200; PMID:15237582
   PubMed Web of Science ®Google Scholar
• Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, Alberg AJ, Harris CC. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009; 18:215-22; PMID:19124500; http://dx.doi.org/10.1158/1055-9965.EPI-08-0705
   PubMed Web of Science ®Google Scholar
• Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito MJ, Oramas J. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80-6; PMID:10080883; http://dx.doi.org/10.1006/cyto.1998.0398
   PubMed Web of Science ®Google Scholar
• Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, Tamura T, Shinkai T, Saijo N. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996; 2:553-9; PMID:9816203
   PubMed Web of Science ®Google Scholar
• Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M, Steffen J. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology 2006; 70:115-25; PMID:16645324; http://dx.doi.org/10.1159/000093002
   PubMed Web of Science ®Google Scholar
• Wojcik E, Jakubowicz J, Skotnicki P, Sas-Korczynska B, Kulpa JK. IL-6 and VEGF in small cell lung cancer patients. Anticancer Res 2010; 30:1773-8; PMID:20592377
   PubMed Web of Science ®Google Scholar
• Necula LG, Chivu-Economescu M, Stanciulescu EL, Bleotu C, Dima SO, Alexiu I, Dumitru A, Constantinescu G, Popescu I, Diaconu CC. IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J Gastrointestin Liver Dis 2012; 21:23-9; PMID:22457856
   PubMed Web of Science ®Google Scholar
• Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009; 9:155; PMID:19457231; http://dx.doi.org/10.1186/1471-2407-9-155
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 2009; 12:95-100; PMID:19562463; http://dx.doi.org/10.1007/s10120-009-0509-8
   PubMed Web of Science ®Google Scholar
• Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005; 8:124-31; PMID:15864720; http://dx.doi.org/10.1007/s10120-005-0315-x
   PubMedGoogle Scholar
• De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21:45-52; PMID:11177580; http://dx.doi.org/10.1089/107999001459150
   PubMed Web of Science ®Google Scholar
• Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012; 3:463-9; PMID:22969912; http://dx.doi.org/10.3892/etm.2011.424
   PubMed Web of Science ®Google Scholar
• Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012; 13:827-37; PMID:22759480; http://dx.doi.org/10.1016/S1470-2045(12)70241-3
   PubMed Web of Science ®Google Scholar
• Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-α: association of pretreatment serum levels with survival. Ann Oncol 2009; 20:1682-7; PMID:19541791; http://dx.doi.org/10.1093/annonc/mdp054
   PubMed Web of Science ®Google Scholar
• Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 2007; 5:51; PMID:17953739; http://dx.doi.org/10.1186/1479-5876-5-51
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004; 22:2371-8; PMID:15197198; http://dx.doi.org/10.1200/JCO.2004.06.121
   PubMed Web of Science ®Google Scholar
• Kallio JP, Tammela TL, Marttinen AT, Kellokumpu-Lehtinen PL. Soluble immunological parameters and early prognosis of renal cell cancer patients. J Exp Clin Cancer Res 2001; 20:523-8; PMID:11876546
   PubMed Web of Science ®Google Scholar
• Favaro D, Santarosa M, Quaia M, Galligioni E. Interleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cells. Urol Oncol 1997; 3:51-8; PMID:21227060; http://dx.doi.org/10.1016/S1078-1439(97)00036-7
   PubMedGoogle Scholar
• Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113:750-7; PMID:18536030; http://dx.doi.org/10.1002/cncr.23615
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11:1815-20; PMID:15756004; http://dx.doi.org/10.1158/1078-0432.CCR-04-1560
   PubMed Web of Science ®Google Scholar
• Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. British J Cancer 2004; 90:2312-6; PMID:15150588; http://dx.doi.org/10.1038/sj.bjc.6601814
   PubMed Web of Science ®Google Scholar
• Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6:2702-6; PMID:10914713
   PubMed Web of Science ®Google Scholar
• Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002; 167:1475-81; PMID:11832773; http://dx.doi.org/10.1016/S0022-5347(05)65348-7
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003; 84:151-9; PMID:14598359; http://dx.doi.org/10.1002/jso.10305
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer J Int Du Cancer 2002; 100:463-71; PMID:12115531; http://dx.doi.org/10.1002/ijc.10496
   PubMed Web of Science ®Google Scholar
• Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J, Schmidt H. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 2012; 22:287-93; PMID:22617301; http://dx.doi.org/10.1097/CMR.0b013e3283550aa5
   PubMed Web of Science ®Google Scholar
• Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V et al. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res 2006; 16:317-23; PMID:16845327; http://dx.doi.org/10.1097/01.cmr.0000200491.00841.5f
   PubMed Web of Science ®Google Scholar
• Mouawad R, Soubrane C, Rixe O, Khayat D, Spano JP. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res 2006; 16:335-40; PMID:16845329
   PubMed Web of Science ®Google Scholar
• Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V, Topuz E. The value of serum levels of IL-6, TNF-α, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Medical Oncol 2005; 22:241-6; PMID:16110135; http://dx.doi.org/10.1385/MO:22:3:241
   PubMed Web of Science ®Google Scholar
• Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005; 15:199-204; PMID:15917702; http://dx.doi.org/10.1097/00008390-200506000-00009
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25:1732-40; PMID:17389336; http://dx.doi.org/10.1200/JCO.2006.08.1331
   PubMed Web of Science ®Google Scholar
• Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997; 127:186-94; PMID:9245223; http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00002
   PubMed Web of Science ®Google Scholar
• Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13:575-82; PMID:7884418
   PubMed Web of Science ®Google Scholar
• Giachelia M, Voso MT, Tisi MC, Martini M, Bozzoli V, Massini G, D'Alo F, Larocca LM, Leone G, Hohaus S. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012; 53:411-6; PMID:21902578; http://dx.doi.org/10.3109/10428194.2011.621566
   PubMed Web of Science ®Google Scholar
• Fabre-Guillevin E, Tabrizi R, Coulon V, Monnereau A, Eghbali H, Soubeyran I, Soubeyran P. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006; 47:603-11; PMID:16690518; http://dx.doi.org/10.1080/10428190500361029
   PubMed Web of Science ®Google Scholar
• el-Far M, Fouda M, Yahya R, el-Baz H. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem 2004; 60:253-8; PMID:15957243; http://dx.doi.org/10.1007/BF03167070
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, Higashihara M, Hirano M. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002; 68:91-100; PMID:12038454; http://dx.doi.org/10.1034/j.1600-0609.2002.01609.x
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993; 53:2118-22; PMID:8481913
   PubMed Web of Science ®Google Scholar
• Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006; 118:3054-61; PMID:16425276; http://dx.doi.org/10.1002/ijc.21688
   PubMed Web of Science ®Google Scholar
• Yamamura M, Yamada Y, Momita S, Kamihira S, Tomonaga M. Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 1998; 100:129-34; PMID:9450801; http://dx.doi.org/10.1046/j.1365-2141.1998.00538.x
   PubMed Web of Science ®Google Scholar
• Egler RA, Burlingame SM, Nuchtern JG, Russell HV. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res 2008; 14:7028-34; PMID:18980999; http://dx.doi.org/10.1158/1078-0432.CCR-07-5017
   PubMed Web of Science ®Google Scholar